Phio Pharmaceuticals Corp. (PHIO) Financial Statements (2024 and earlier)

Company Profile

Business Address 11 APEX DRIVE, SUITE 300A
MARLBOROUGH, MA 01752
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,490,0008,407,00011,307,0009,035,00011,781,00014,484,000
Cash and cash equivalents8,490,0008,407,00011,307,0009,035,00011,781,00014,484,000
Prepaid expense      843,000
Other undisclosed current assets832,000921,000728,000369,000665,00050,000
Total current assets:9,322,0009,328,00012,035,0009,404,00012,446,00015,377,000
Noncurrent Assets
Operating lease, right-of-use asset 33,00066,00098,000130,000161,000192,000
Property, plant and equipment6,000142,000157,000167,000183,000198,000
Other noncurrent assets3,0003,0006,0006,00024,00024,000
Total noncurrent assets:42,000211,000261,000303,000368,000414,000
TOTAL ASSETS:9,364,0009,539,00012,296,0009,707,00012,814,00015,791,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,599,0002,256,0002,288,0002,258,0001,804,0002,062,000
Accounts payable657,000173,000641,000902,000779,000543,000
Accrued liabilities942,0002,083,0001,647,0001,356,0001,025,0001,519,000
Other undisclosed current liabilities 35,00070,000104,000138,000135,000132,000
Total current liabilities:1,634,0002,326,0002,392,0002,396,0001,939,0002,194,000
Noncurrent Liabilities
Long-term debt and lease obligation:      70,000
Liabilities, other than long-term debt     35,000 
Operating lease, liability     35,00070,000
Other undisclosed noncurrent liabilities      (70,000)
Total noncurrent liabilities:     35,00070,000
Total liabilities:1,634,0002,326,0002,392,0002,396,0001,974,0002,264,000
Equity
Equity, attributable to parent7,730,0007,213,0009,904,0007,311,00010,838,00013,527,000
Common stock      1,000
Additional paid in capital146,936,000144,524,000144,435,000139,293,000139,218,000139,175,000
Accumulated deficit(139,206,000)(137,311,000)(134,531,000)(131,982,000)(128,380,000)(125,649,000)
Other undisclosed equity     2,000 
Total equity:7,730,0007,213,0009,904,0007,311,00010,840,00013,527,000
TOTAL LIABILITIES AND EQUITY:9,364,0009,539,00012,296,0009,707,00012,814,00015,791,000

Income Statement (P&L) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Operating expenses(1,899,000)(2,776,000)(2,547,000)(3,602,000)(2,730,000)(3,571,000)
Operating loss:(1,899,000)(2,776,000)(2,547,000)(3,602,000)(2,730,000)(3,571,000)
Nonoperating income (expense)4,000(4,000)(2,000) (1,000)(5,000)
Loss from continuing operations:(1,895,000)(2,780,000)(2,549,000)(3,602,000)(2,731,000)(3,576,000)
Loss before gain (loss) on sale of properties:(3,576,000)
Net loss available to common stockholders, diluted:(1,895,000)(2,780,000)(2,549,000)(3,602,000)(2,731,000)(3,576,000)

Comprehensive Income (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(1,895,000)(2,780,000)(2,549,000)(3,602,000)(2,731,000)(3,576,000)
Comprehensive loss, net of tax, attributable to parent:(1,895,000)(2,780,000)(2,549,000)(3,602,000)(2,731,000)(3,576,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: